Sanofi SA ADR 1/2/EO 2

SNW2 
(XETRA) 
 

News about Sanofi SA ADR 1/2/EO 2

  • Local
  • International
  • Company messages

Popular news

1
Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting
2
Holding(s) in Company
3
G4S plc UK DK : Disposal
4
Fingerprint Cards adjusts its 2016 revenue forecast
5
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
6
MYLAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Mylan N.V. – MYL
7
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
8
Appointment of Joint Corporate Broker
9
INVESTOR ALERT: Stull, Stull & Brody Filed a Securities Class Action Lawsuit on Behalf of Purchasers of Arrowhead Pharmaceuticals, Inc. Common Stock and Encourages Shareholders with Losses to Contact the Firm
10
Alliance Trust PLC : Net Asset Value(s)

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
08 December 2016 21:58:49
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20161205.1 - EUROWEB1 - 2016-12-08 22:58:49 - 2016-12-08 21:58:49 - 1000 - Website: OKAY